About UsEPS Innovative Medicine is the first drug discovery company of the EPS Group.

EPS Innovative Medicine is the first drug discovery company of the EPS Group.

Message from the President

EPS Innovative Medicine (Japan) Ltd. started on October 8, 2021, as the first drug discovery company of EPS Group.
The drug discovery environment in Europe, the U.S., Asia, and Japan is undergoing dramatic change. For many years, research and development has been carried out with huge investment of resources by major pharmaceutical companies. Today, however, some 80% of all drug and medical device candidates are being discovered and developed by start-up biotechnology – venture companies around the world.
In Japan, the number of potential drug and medical products researched in academia is increasing. Start-up drug development venture companies, are also proliferating, with over 1,000 such enterprises now in operation.
As was the case in the past, such clinical development of drugs and medical devices demands a great deal of knowledge, know-how, and financial resources. In Japan, public organizations are providing various types of support for drug and medical product development and are planning to enhance their involvement. However, their support does not appear to be sufficient to satisfy the diverse needs of academia and the venture companies.
In contrast to conventional CROs, EPS Innovative Medicine is intending to provide a one-stop total solutions for new drug and medical product research and developments based on knowledge and know-how accumulated over many years by the EPS Group. We aim to satisfy the requirements of drug and medical product venture enterprises and academia, both within Japan and overseas, to help them enter Japanese and overseas markets, particularly those of China and Asia.
To that end, EPS Innovative Medicine is designing a new drug discovery business model and a new ecosystem to “interface” between discovery of potential drug and medical products by venture companies/academia and patients in Japan and Asia. Please read, in the following pages of this website, the detailed description and benefits of EPS’ new drug discovery and ecosystem model.
We look forward to your ongoing and generous support.

Tomohisa HayakawaPresident and Representative Corporate Officer

Corporate Profile 

Corporate Name EPS Innovative Medicine (Japan) Co., Ltd.
Established October 8, 2021
Location EPS Holdings, Inc. Head Office Building
1-8, Tsukudo-cho, Shinjuku-ku, Tokyo
Capital JPY50 million
Parent company EPS Holdings, Inc.
Representative
Director
Tomohisa Hayakawa
Officers and auditor
Chairman & Corporate Officer Satoshi Okoso
President & Representative Corporate Officer Tomohisa Hayakawa
Corporate Officer Gao Feng
Corporate Officer Kosuke Kuronuma
Corporate Officer Shinji Kondoh
Corporate Officer & Auditor Xia Xiangming
Business description
  • Professional services for clinical development of drugs, medical devices, etc. (clinical development planning, CRO services)
  • Investment in bio-ventures, licensing
  • Clinical research and development of own products
  • Other related services

Contact Us

Please feel free to contact us.